U.S. Stem Cell, Inc. USRM

Company Overview

U.S. Stem Cell, Inc. (OTC: USRM) is a biotechnology and regenerative medicine company focused on stem cell processing, cell-based therapeutics, and regenerative medicine services. The company has historically operated in the regenerative healthcare sector through a combination of stem cell banking, physician training, laboratory services, and the development of adipose-derived stem cell technologies. Public filings and company disclosures indicate that its activities have included stem cell collection and processing systems, clinical support services, and physician-focused regenerative medicine programs. The company has also been associated with direct-to-consumer regenerative treatment offerings through affiliated clinical operations.

The company evolved from Bioheart, Inc., a cardiac cell therapy developer founded in the early 2000s, before rebranding to U.S. Stem Cell, Inc. as it broadened its focus beyond cardiovascular therapies into regenerative medicine and stem cell applications. Historically, the company positioned itself around minimally invasive autologous stem cell procedures using adipose tissue-derived cells. Its strategic positioning centered on physician education, proprietary processing systems, and regenerative medicine infrastructure, though the company has faced significant regulatory scrutiny and legal challenges related to certain stem cell treatment activities. Information regarding current operational scale and commercial traction is limited in recent public disclosures, and some operational details are inconclusive based on available public sources.